Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
BMC Geriatr ; 18(1): 268, 2018 11 06.
Artigo em Inglês | MEDLINE | ID: mdl-30400833

RESUMO

BACKGROUND: The complex physiology underpinning the frailty syndrome is responsible for the absence of robust biomarkers that can be used for screening, diagnostic and/or prognostic purposes and has made clinical implementation difficult. Considering socially vulnerable populations, who have poor health status and increased morbidity and mortality, this scenario is even more complex. However, to the best of our knowledge, there are no studies available to investigate frailty biomarkers in socially vulnerable populations. Thus, the aim of this cross-sectional study was to identify potential blood-based biomarkers of frailty in a socially vulnerable population. METHODS: A sample consisting of 347 community-dwelling older people living in a context of high social vulnerability was divided into non-frail (robust), pre-frail and frail groups, according to modified Fried frailty phenotype criteria. Blood samples were collected and analyzed for basic metabolic parameters and for inflammatory cytokines. RESULTS: Levels of Interleukin-1α (IL-1α) and Tumor Necrosis Factor α (TNF-α) were significantly higher in pre-frail subjects, compared to non-frail ones. Tumor Necrosis Factor ß (TNF-ß) levels presented higher values in the frail compared to non-frail individuals. Interleukin-6 (IL-6) levels in pre-frail and frail subjects were significantly higher compared to the levels of non-frail subjects. Using an ordinal regression analysis, we observed that socially vulnerable older people at higher risk of developing frailty were subjects above 80 years old (OR: 2.5; 95% CI: 1.1-5.6) and who presented higher levels of TNF-ß (≥0.81 pg/mL, OR: 2.53; 95% CI: 1.3-4.9). CONCLUSION: As vulnerable populations continue to age, it is imperative to have a greater understanding of the frailty condition, identifying novel potential blood-based biomarkers. The results presented here could help to implement preventive healthcare strategies by evaluating frailty and at the same time measuring a set of inflammatory biomarkers, paying special attention to TNF-ß plasmatic levels.


Assuntos
Idoso Fragilizado/estatística & dados numéricos , Fragilidade/sangue , Avaliação Geriátrica/métodos , Vida Independente , Linfotoxina-alfa/sangue , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Brasil/epidemiologia , Estudos Transversais , Feminino , Fragilidade/epidemiologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade
2.
Immunol Res ; 64(5-6): 1168-1178, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27592234

RESUMO

The aim of this study was to explore the association between some SNPs of the TNF, LTA, IL1B and IL10 genes with cytokine concentrations and clinical course in Colombian septic patients. We conducted a cross-sectional study to genotype 415 septic patients and 205 patients without sepsis for the SNPs -308(G/A) rs1800629 of TNF; +252 (G/A) rs909253 of LTA; -511(A/G) rs16944 and +3953(C/T) rs1143634 of IL1B; and -1082(A/G) rs1800896, -819(C/T) rs1800871 and -592(C/A) rs1800872 of IL10. The association of theses SNPs with the following parameters was evaluated: (1) the presence of sepsis; (2) severity and clinical outcomes; (3) APACHE II and SOFA scores; and (4) procalcitonin, C-reactive protein, tumor necrosis factor, lymphotoxin alpha, interleukin 1 beta and interleukin 10 plasma concentrations. We found an association between the SNP LTA +252 with the development of sepsis [OR 1.29 (1.00-1.68)]; the SNP IL10 -1082 with sepsis severity [OR 0.53 (0.29-0.97)]; the TNF -308 with mortality [OR 0.33 (0.12-0.95)]; and the IL10 -592 and IL10 -1082 with admission to the intensive care unit (ICU) [OR 3.36 (1.57-7.18)] and [OR 0.18 (0.04-0.86)], respectively. None of the SNPs were associated with cytokine levels, procalcitonin and C-reactive protein serum concentrations, nor with APACHE II and SOFA scores. Our results suggest that these genetic variants play an important role in the development of sepsis and its clinical course.


Assuntos
Interleucina-10/genética , Interleucina-1beta/genética , Linfotoxina-alfa/genética , Sepse/imunologia , Fator de Necrose Tumoral alfa/genética , Proteína C-Reativa/metabolismo , Calcitonina/sangue , Colômbia , Cuidados Críticos , Estudos Transversais , Progressão da Doença , Estudos de Associação Genética , Predisposição Genética para Doença , Genótipo , Humanos , Interleucina-10/sangue , Interleucina-1beta/sangue , Linfotoxina-alfa/sangue , Polimorfismo de Nucleotídeo Único , Sepse/genética , Sepse/mortalidade , Análise de Sobrevida , Fator de Necrose Tumoral alfa/sangue
3.
Campinas; s.n; 2009. 86 p. tab, graf.
Tese em Português | LILACS | ID: lil-604068

RESUMO

Objetivo: Investigar a eficácia da ultrafiltração na remoção de mediadores inflamatórios liberados pela circulação extracorpórea e correlacionar ultrafiltração com alterações da função orgânica de acordo com o "Seqüential Organ Failure Assessment Score". Métodos: Quarenta pacientes foram incluídos e randomizados em dois grupos: "sem ultrafiltração" (n=20; Grupo I) e "ultrafiltração" (n=20; Grupo II). Complementos 3 e 4 ativados, interleucina 1beta, 6, 8 e fator de necrose tumoral alfa foram dosados antes da indução anestésica (T1), 5 minutos antes da circulação extracorpórea (T2), no líquido ultrafiltrado (T3), 30 minutos (T4), 6 (T5), 12 (T6), 24 (T7), 36 (T8) e 48 (T9) horas após término da circulação extracorpórea. "Sequential Organ Failure Assessment Score" foi avaliado nos tempos 1, 6 e 9. Significância estatística foi estabelecida com...


Objective: To investigate the effectiveness of ultrafiltration in removing inflammatory mediators released by cardiopulmonary bypass and to correlate ultrafiltration with alterations in organic function according to the Sequential Organ Failure Assessment Score. Methods: Forty patients were included and randomized into two groups: "no ultrafiltration" (n=20; Group I) and "ultrafiltration" (n=20; Group II). Activated complement 3 and 4, interleukins 1beta, 6, 8 and tumor necrosis factor alfa were measured prior to anesthesia induction (Time 1), 5 minutes before cardiopulmonary bypass (Time 2), in the ultrafiltrated fluid (Time 3), 30 minutes (Time 4), and 6 (Time 5), 12 (Time 6), 24 (Time 7), 36 (Time 8) and 48 (Time 9) hours following cardiopulmonary bypass. Sequential Organ Failure Assessment Score was evaluated at Time 1, 6 and 9. Statistical significance was established...


Assuntos
Humanos , Citotoxinas , Circulação Extracorpórea , Interleucina-1 , /sangue , /sangue , Linfotoxina-alfa/sangue , Insuficiência de Múltiplos Órgãos/diagnóstico , Ultrafiltração
4.
Braz Dent J ; 19(1): 3-8, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19031648

RESUMO

Advances in diagnostic research are moving towards methods whereby the periodontal risk can be identified and quantified by objective measures using biomarkers. Patients with periodontitis may have elevated circulating levels of specific inflammatory markers that can be correlated to the severity of the disease. The purpose of this study was to evaluate whether differences in the serum levels of inflammatory biomarkers are differentially expressed in healthy and periodontitis patients. Twenty-five patients (8 healthy patients and 17 chronic periodontitis patients) were enrolled in the study. A 15 mL blood sample was used for identification of the inflammatory markers, with a human inflammatory flow cytometry multiplex assay. Among 24 assessed cytokines, only 3 (RANTES, MIG and Eotaxin) were statistically different between groups (p<0.05). In conclusion, some of the selected markers of inflammation are differentially expressed in healthy and periodontitis patients. Cytokine profile analysis may be further explored to distinguish the periodontitis patients from the ones free of disease and also to be used as a measure of risk. The present data, however, are limited and larger sample size studies are required to validate the findings of the specific biomarkers.


Assuntos
Periodontite Crônica/sangue , Mediadores da Inflamação/sangue , Biomarcadores/sangue , Quimiocina CCL2/sangue , Quimiocina CCL3/sangue , Quimiocina CCL4/sangue , Quimiocina CCL5/sangue , Quimiocina CXCL9/sangue , Quimiocinas CC/sangue , Citocinas/sangue , Proteína Ligante Fas/sangue , Fator 2 de Crescimento de Fibroblastos/sangue , Hemorragia Gengival/sangue , Fator Estimulador de Colônias de Granulócitos/sangue , Fator Estimulador de Colônias de Granulócitos e Macrófagos/sangue , Humanos , Interferon gama/sangue , Interleucina-9/sangue , Interleucinas/sangue , Linfotoxina-alfa/sangue , Perda da Inserção Periodontal/sangue , Bolsa Periodontal/sangue , Fator de Crescimento Transformador beta/sangue
5.
Microbes Infect ; 10(10-11): 1150-7, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18606242

RESUMO

The hantavirus pulmonary syndrome (HPS) is an emerging syndrome in the Americas. The disease results from intense immune activation and changes in vascular permeability. The aim of this study was to determine the profile of serum cytokines in HPS patients looking for correlation with the clinical parameters, severity and outcome of illness. Studying 21 HPS patients, we found that IL-6 may have an important role in the pathogenesis of HPS, being associated with fatal outcome. Our results also support a mixed Th1/Th2 immune response during the course of HPS and that the magnitude of Th1 response effector cytokines is correlated to HPS severity. The decreased levels of TGF-beta observed in HPS patients suggest that immunoregulatory activity could be damaged in these patients.


Assuntos
Citocinas/sangue , Síndrome Pulmonar por Hantavirus/diagnóstico , Síndrome Pulmonar por Hantavirus/imunologia , Células Th1/imunologia , Células Th2/imunologia , Pressão Sanguínea , Progressão da Doença , Orthohantavírus/patogenicidade , Síndrome Pulmonar por Hantavirus/patologia , Humanos , Interleucinas/sangue , Linfotoxina-alfa/sangue , Óxido Nítrico/sangue , Prognóstico
6.
Braz. dent. j ; Braz. dent. j;19(1): 3-8, 2008. tab
Artigo em Inglês | LILACS | ID: lil-481120

RESUMO

Advances in diagnostic research are moving towards methods whereby the periodontal risk can be identified and quantified by objective measures using biomarkers. Patients with periodontitis may have elevated circulating levels of specific inflammatory markers that can be correlated to the severity of the disease. The purpose of this study was to evaluate whether differences in the serum levels of inflammatory biomarkers are differentially expressed in healthy and periodontitis patients. Twenty-five patients (8 healthy patients and 17 chronic periodontitis patients) were enrolled in the study. A 15 mL blood sample was used for identification of the inflammatory markers, with a human inflammatory flow cytometry multiplex assay. Among 24 assessed cytokines, only 3 (RANTES, MIG and Eotaxin) were statistically different between groups (p<0.05). In conclusion, some of the selected markers of inflammation are differentially expressed in healthy and periodontitis patients. Cytokine profile analysis may be further explored to distinguish the periodontitis patients from the ones free of disease and also to be used as a measure of risk. The present data, however, are limited and larger sample size studies are required to validate the findings of the specific biomarkers.


Avanços no diagnóstico da doença periodontal levam a métodos nos quais o risco e atividade da doença periodontal podem ser identificados e quantificados por biomarcadores. Pacientes com periodontite podem apresentar elevados níveis circulatórios de marcadores inflamatórios específicos que podem ser correlacionados com a severidade da doença. Portanto, o objetivo desse estudo foi avaliar as diferenças nos níveis séricos de biomarcadores inflamatórios em pacientes saudáveis e com doença periodontal. Foram incluídos no estudo 25 pacientes (8 saudáveis e 17 com periodontite crônica). Uma amostra de 15 mL de sangue foi obtida para identificar os marcadores inflamatórios simultaneamente utilizando Array de proteínas através de citometria de fluxo. De 24 citocinas inflamatórias analisadas, apenas 3 (RANTES, MIG e Eotaxina) apresentaram diferenças estatisticamente significantes (p<0,05) entre os dois grupos. Conclui-se que alguns marcadores inflamatórios selecionados apresentam diferença de concentração em pacientes com periodontite e saudáveis. A análise do perfil de citocinas pode ser utilizada tanto para distinguir pacientes periodontais de pacientes saudáveis, como para medir o risco à doença. Contudo, mais estudos com número maior de amostras são necessários para validar os achados sobre os biomarcadores específicos.


Assuntos
Humanos , Periodontite Crônica/sangue , Mediadores da Inflamação/sangue , Biomarcadores/sangue , /sangue , /sangue , /sangue , /sangue , Quimiocina CXCL9/sangue , Quimiocinas CC/sangue , Citocinas/sangue , Proteína Ligante Fas/sangue , /sangue , Hemorragia Gengival/sangue , Fator Estimulador de Colônias de Granulócitos/sangue , Fator Estimulador de Colônias de Granulócitos e Macrófagos/sangue , Interferon gama/sangue , Interleucina-9/sangue , Interleucinas/sangue , Linfotoxina-alfa/sangue , Perda da Inserção Periodontal/sangue , Bolsa Periodontal/sangue , Fator de Crescimento Transformador beta/sangue
7.
J Infect Dis ; 196(12): 1836-43, 2007 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-18190265

RESUMO

BACKGROUND: Chagas disease, caused by Trypanosoma cruzi infection, displays clinical heterogeneity and may be attributable to differential genetic susceptibility. Chronic Chagas cardiomyopathy (CCC) develops only in a subset of T. cruzi-infected individuals and may lead to heart failure that has a worse clinical course and that leads to reduced life expectancy, compared with heart failure of other etiologies. Proinflammatory cytokines play a key role in the development of CCC. Clinical, genetic, and epidemiological studies have linked lymphotoxin-alpha (LTA), a proinflammatory cytokine, to coronary artery disease and myocardial infarction. METHODS: We used polymerase chain reaction to genotype the LTA +80A-->C and LTA +252A-->G variants in 169 patients with CCC and in 76 T. cruzi-infected asymptomatic (ASY) patients. RESULTS: Homozygosity with respect to the LTA +80C and LTA +252G alleles was significantly more frequent in the patients with CCC than in the ASY patients (homozygosity for LTA +80C, 47% vs. 33%; homozygosity for LTA +252G, 16% vs. 8%). Haplotype LTA +80A-252A was associated with protection against CCC, whereas haplotype LTA +80C-252G was associated with susceptibility to CCC. Furthermore, homozygosity for the LTA +80A allele correlated with the lowest levels of plasmatic tumor-necrosis factor-alpha. CONCLUSIONS: Our results suggest that the study of genetic variations in patients with Chagas disease may help in the identification of individuals at increased risk of progressing to CCC and, by providing early treatment, reduce the morbidity and mortality associated with this disease.


Assuntos
Cardiomiopatia Chagásica/genética , Linfotoxina-alfa/genética , Trypanosoma cruzi/crescimento & desenvolvimento , Animais , Cardiomiopatia Chagásica/sangue , Cardiomiopatia Chagásica/imunologia , Feminino , Frequência do Gene/genética , Predisposição Genética para Doença , Genótipo , Haplótipos/genética , Humanos , Linfotoxina-alfa/sangue , Linfotoxina-alfa/imunologia , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético , Trypanosoma cruzi/imunologia , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/imunologia
8.
Rev. Inst. Med. Trop. Säo Paulo ; Rev. Inst. Med. Trop. Säo Paulo;38(2): 113-8, mar.-abr. 1996. ilus, tab
Artigo em Inglês | LILACS | ID: lil-175909

RESUMO

Avaliacao de TNF-alfa em pacientes com calazar tem despertado grande interesse devido ao seu papel no sistema imunologico e a sua atividade caquetizante. O objetivo deste estudo foi examinar a associacao entre os niveis plasmaticos de TNF-alfa, medidos atraves de sua imunorreatividade (ELISA) e bioatividade (ensaio citotoxico sobre as celulas L-929), e as manifestacoes clinicas da leishmaniose visceral. Amostras de 19 pacientes foram obtidas para determinacao do TNF-alfa antes, durante e apos a terapia antimonial, utilizando o ensaio de citotoxidade (todos os pacientes) e o ELISA (14 pacientes). Resultados discrepantes entre os ensaios de citotoxidade e o ELISA foram observados...


Assuntos
Humanos , Masculino , Feminino , Citocinas/metabolismo , Leishmaniose Visceral/terapia , Fator de Necrose Tumoral alfa/metabolismo , Antimônio/uso terapêutico , Ensaio de Imunoadsorção Enzimática , Linfotoxina-alfa/sangue , Plasma/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA